Alpha 2.0
Login Register
» Articles » PMID: 8461645

Use of Tumour Marker Immunoreactivity to Identify Primary Site of Metastatic Cancer

Overview
Journal BMJ
Specialty General Medicine
Date 1993 Jan 30
PMID 8461645
Citations 5
Authors
A R Gamble
J A Bell
J E Ronan
D Pearson
I O Ellis
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine whether variations in the expression of tumour related antigens can predict the origin of tumours.

Design: Immunohistological study of tumour marker expression in primary adenocarcinomas and respective metastatic deposits. Antibodies to the following tumour markers were used: polymorphic epithelial mucin (NCRC-11 and SM3), carcinoembryonic antigen, carcinoembryonic antigen with non-specific antigen co-specificity, CA125, CA19.9, prostate specific antigens, and thyroglobulin.

Setting: Histopathology department of teaching hospital.

Subjects: 100 pathology sections of metastatic adenocarcinoma and their related primary tumours.

Main Outcome Measures: Concordance of reactivity between primary and metastatic tumours. Reactivity profiles of tumour sites.

Results: The correct primary site of origin was predicted in 70% (33/47) of tumours in men and 54% (27/43) tumours in women with antibodies SM3, 288, CA19.9, CA125, and PSA (men only). Specificities ranged from 68% for breast tumour to 98% for prostate tumour.

Conclusion: Use of tumour markers in patients presenting with metastatic adenocarcinoma of unknown origin can help localise the probable primary sites and reduce the need for extensive and expensive imaging techniques.

Citing Articles

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth J, Greco F Virchows Arch. 2014; 464(4):393-402.

PMID: 24487792 DOI: 10.1007/s00428-014-1545-2.

Isolated multiple bilateral thyroid metastases from prostatic adenocarcinoma: case report and literature review.

Albsoul N, Obeidat F, Hadidy A, Alzoubi M, Taib A, Shahait A Endocr Pathol. 2013; 24(1):36-9.

PMID: 23307110 DOI: 10.1007/s12022-013-9232-4.

Search for primary cancer.

Rodger A BMJ. 1993; 306(6884):1070.

PMID: 8490522 PMC: 1677031. DOI: 10.1136/bmj.306.6884.1070-b.

Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

Croce M, Price M, Segal-Eiras A Cancer Immunol Immunother. 1995; 40(2):132-7.

PMID: 7882384 PMC: 11037836. DOI: 10.1007/BF01520296.

Tumour markers and primary site of cancer.

Pinhorn A BMJ. 1993; 306(6878):651.

PMID: 7873935 PMC: 1676924. DOI: 10.1136/bmj.306.6878.651.

References
1.
Berchuck A, Soisson A, Clarke-Pearson D, Soper J, Boyer C, Kinney R . Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res. 1989; 49(8):2091-5. View
2.
Nystrom J, Weiner J, Wolf R, Bateman J, Viola M . Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA. 1979; 241(4):381-3. View
3.
Ellis I, Robins R, Elston C, Blamey R, Ferry B, Baldwin R . A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology. 1984; 8(3):501-16. DOI: 10.1111/j.1365-2559.1984.tb02360.x. View
4.
Hamaya K, Doi K, Yoshizawa S, Motoi M . [An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?]. Gan No Rinsho. 1988; 34(14):1956-60. View
5.
Hammond M, Sause W, Martz K, Pilepich M, Asbell S, Rubin P . Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer. 1989; 63(3):461-6. DOI: 10.1002/1097-0142(19890201)63:3<461::aid-cncr2820630312>3.0.co;2-j. View